Related Experiment Video
Updated: Jan 6, 2026
12:27
Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt
Published on: May 7, 2015
16.8K
Using octreotide for refractory ascites after liver transplantation
Oana-Anisa Nutu1, Alejandro Manrique Municio1, Alberto Marcacuzco Quinto1
1Unidad de Cirugía HBP y Trasplante de Órganos Abdo, Hospital Universitario 12 de Octubre.
Revista Espanola De Enfermedades Digestivas
|October 10, 2019
Summary
Refractory ascites post-liver transplant can be challenging. Octreotide effectively reduced portal flow and pressure, resolving ascites in a patient unresponsive to splenic embolization.
Area of Science:
- Gastroenterology and Hepatology
- Transplantation Medicine
Background:
- Refractory ascites significantly impacts survival and quality of life in liver transplant recipients.
- Portal hyperflow is a primary cause of refractory ascites following liver transplantation.
Observation:
- A patient with refractory ascites post-liver transplant showed persistent fluid accumulation despite splenic embolization.
- Splenic revascularization by short gastric vessels rendered repeat embolization unfeasible.
Findings:
- Octreotide, a somatostatin analog, induced splanchnic vasoconstriction, reducing portal flow and venous pressure.
- Four months of octreotide treatment led to complete resolution of ascites and improved clinical status.
Implications:
- Octreotide offers a viable therapeutic option for refractory ascites in liver transplant patients when other interventions fail.
- Understanding vascular dynamics is crucial for managing post-transplant ascites.
- This case highlights the potential of pharmacologic management in complex post-transplant complications.
